301 related articles for article (PubMed ID: 31282310)
1. Medical treatment for benign prostatic hyperplasia: Where do we stand?
Rossanese M; Crestani A; Inferrera A; Giannarini G; Bartoletti R; Tubaro A; Ficarra V
Urologia; 2019 Aug; 86(3):115-121. PubMed ID: 31282310
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
Sarma AV; Wei JT
N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
[No Abstract] [Full Text] [Related]
4. Benign Prostatic Hyperplasia.
Langan RC
Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
[TBL] [Abstract][Full Text] [Related]
5. Treatment of benign prostatic hyperplasia.
Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
[No Abstract] [Full Text] [Related]
6. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
7. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
9. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
12. A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned.
Tubaro A; Speakman M; de la Taille A; Martínez-Piñeiro L; Berges R; Patel A; Bjartell A; Caris C; Witjes W
J Urol; 2021 Apr; 205(4):1145-1152. PubMed ID: 33259270
[TBL] [Abstract][Full Text] [Related]
13. α-Blockers, 5-α-Reductase Inhibitors, Acetylcholine, β3 Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?
Chughtai B; Thomas D; Kaplan S
Urol Clin North Am; 2016 Aug; 43(3):351-6. PubMed ID: 27476127
[TBL] [Abstract][Full Text] [Related]
14. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.
Homma Y; Gotoh M; Kawauchi A; Kojima Y; Masumori N; Nagai A; Saitoh T; Sakai H; Takahashi S; Ukimura O; Yamanishi T; Yokoyama O; Yoshida M; Maeda K
Int J Urol; 2017 Oct; 24(10):716-729. PubMed ID: 28748576
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
Ückert S; Kedia GT; Tsikas D; Simon A; Bannowsky A; Kuczyk MA
World J Urol; 2020 Jun; 38(6):1423-1435. PubMed ID: 31506747
[TBL] [Abstract][Full Text] [Related]
16. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
Marberger M
Adv Ther; 2013 Apr; 30(4):309-19. PubMed ID: 23584673
[TBL] [Abstract][Full Text] [Related]
17. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
[TBL] [Abstract][Full Text] [Related]
19. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
20. Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study.
Gravas S
Eur Urol; 2015 Aug; 68(2):338-9. PubMed ID: 26149729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
